Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of$ 1.02. This compares to loss of $1.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -28.43%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 1.16 per share when it actually produced a loss of $1.33, delivering a surprise of -14.66%. Over the last four quarters, the c ...